Chronic Refractory Idiopathic Urticaria  

作　　者：Indira Acharya Ashik Pokharel Ashbina Pokharel Lanaya Williams Smith Indira Acharya;Ashik Pokharel;Ashbina Pokharel;Lanaya Williams Smith(Department of Internal Medicine, MedStar Union Memorial Hospital, Baltimore, Maryland, USA;Department of Internal Medicine, William Beaumont Hospital, Royal Oak, Michigan, USA;Department of Internal Medicine, MedStar Good Samaritan Hospital, Baltimore, Maryland, USA)

机构地区：[1]Department of Internal Medicine, MedStar Union Memorial Hospital, Baltimore, Maryland, USA [2]Department of Internal Medicine, William Beaumont Hospital, Royal Oak, Michigan, USA [3]Department of Internal Medicine, MedStar Good Samaritan Hospital, Baltimore, Maryland, USA

出　　处：《Journal of Biosciences and Medicines》2023年第11期13-22,共10页生物科学与医学（英文）

摘　　要：Background: Chronic spontaneous urticaria (CSU) is a complex medical condition characterized by substantial morbidity and a negative impact on one’s quality of life. There are several treatment approaches available, tailored to the severity of the condition, which can enhance overall quality of life. Aim: In this article, we outline a systematic approach to managing chronic urticaria, while also elucidating the available treatment strategies for cases that prove resistant to conventional therapies. To illustrate our points, we present a clinical case as a practical example. Case Presentation: Here, we present a patient with CSU since childhood who presented in the context of refractory hives and generalized arthralgia that responded well to omalizumab therapy with no further relapse. Conclusion: Omalizumab is a biological agent that offers a potential treatment option for CSU. It is available for individuals twelve years and older who have not responded well to conventional treatments. It has demonstrated good efficacy with a relatively low rate of clinically significant adverse effects. Nonetheless, there is a dearth of research regarding the optimal method for tapering the dosage and determining the duration of treatment.Background: Chronic spontaneous urticaria (CSU) is a complex medical condition characterized by substantial morbidity and a negative impact on one’s quality of life. There are several treatment approaches available, tailored to the severity of the condition, which can enhance overall quality of life. Aim: In this article, we outline a systematic approach to managing chronic urticaria, while also elucidating the available treatment strategies for cases that prove resistant to conventional therapies. To illustrate our points, we present a clinical case as a practical example. Case Presentation: Here, we present a patient with CSU since childhood who presented in the context of refractory hives and generalized arthralgia that responded well to omalizumab therapy with no further relapse. Conclusion: Omalizumab is a biological agent that offers a potential treatment option for CSU. It is available for individuals twelve years and older who have not responded well to conventional treatments. It has demonstrated good efficacy with a relatively low rate of clinically significant adverse effects. Nonetheless, there is a dearth of research regarding the optimal method for tapering the dosage and determining the duration of treatment.

关 键 词：OMALIZUMAB Biological Agent Chronic Spontaneous Urticaria (CSU) Conventional Treatment RELAPSE 

分 类 号：R97[医药卫生—药品]